
1. bmj open. 2011 jan 1;1(2):e000167. doi: 10.1136/bmjopen-2011-000167.

effectiveness safety a-h1n1 vaccine children: hospital-based
case-control study.

italian multicenter study group drug vaccine safety children.

objective verify whether vaccination a-h1n1 virus the
paediatric population effective preventing occurrence of
influenza-like illness (ili) associated adverse events special
interest. design, setting patients case-control analysis performed as
part surveillance children hospitalised emergency departments
of eight paediatric hospitals/wards ili, neurological disorders,
non-infectious muco-cutaneous diseases vasculitis, thrombocytopaenia and
gastroduodenal lesions. results among 736 children enrolled november 2009 to
august 2010, 25 vaccinated pandemic vaccine. 268
children admitted diagnosis compatible adverse events special
interest, six received a-h1n1 vaccine, although none adverse
events occurred within predefined risk windows. 35 children 244
admitted diagnosis ili underwent laboratory testing: 11 positive
and 24 negative a-h1n1 virus. none a-h1n1 positive children had
received pandemic vaccine. ili associated influenza
vaccination 0.9 (95% ci 0.1 5.5). conclusions study provides
additional information benefit-risk profile pandemic vaccine. no
sign risk associated influenza a-h1n1 vaccine used italy was
found, although several limitations observed: italy, pandemic vaccination
coverage low, epidemic almost mid december 2009 the
a-h1n1 laboratory test performed epidemic phase (in <10% of
children). study supports importance existing network of
hospitals evaluation signals relevant new vaccines drugs.

doi: 10.1136/bmjopen-2011-000167 
pmcid: pmc3191592
pmid: 22021877 

